Use of X-ray crystallography for the characterization of single crystals grown in steroid containing transdermal drug delivery systems

被引:21
作者
Lipp, R [1 ]
Müller-Fahrnow, A [1 ]
机构
[1] Schering AG, Drug Delivery Syst, D-13342 Berlin, Germany
关键词
estradiol; gestodene; transdermal drug delivery system; X-ray crystallography;
D O I
10.1016/S0939-6411(98)00055-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Target of the study was to characterize crystals which had grown in steroid-containing matrix patches during short-term storage and to thereby establish a rationale for the inhibition of crystal formation in those patches in general. Matrix type transdermal drug delivery systems (IDDS) containing either 2.2% gestodene or 3.3% estradiol were free of crystals directly after their production. However, crystals of up to 800 mu m in length grew during 3 months of storage at ambient temperature. The application of several analytical methods did not help to identify the crystals. This was mainly due to the fact that the adhesive matrix surrounding the crystals could not be fully removed in the course of sample preparation with routine laboratory methods and thus impaired DSC, FTIR microscopy and hot stage polarized microscopy. However, within X-ray diffractometry, the residual amorphous parch matrix did not hamper the measurement of the crystals. Thus, they were identified as estradiol hemihydrate and gestodene form I, respectively. These results suggest that steroid-containing matrix TDDS should be stabilized against drug recrystallization e.g. by the addition of suitable crystallization inhibitors. Furthermore, systems containing estradiol may be stabilized by efficient removal water. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:133 / 138
页数:6
相关论文
共 15 条
[1]  
BARRY BW, 1983, DERMATOLOGICAL FORMU, P160
[2]   DETECTION AND CHARACTERIZATION OF POLYMORPHIC MODIFICATIONS OF THE ANXIOLYTIC DRUG ABECARNIL [J].
BOCK, M ;
DEPKE, G ;
EGNER, U ;
MULLERFAHRNOW, A ;
WINTER, G .
TETRAHEDRON, 1994, 50 (46) :13125-13134
[3]   CRYSTAL AND MOLECULAR STRUCTURE OF ESTRADIOL HEMIHYDRATE [J].
BUSETTA, B ;
HOSPITAL, M .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL CRYSTALLOGRAPHY AND CRYSTAL CHEMISTRY, 1972, B 28 (FEB15) :560-&
[4]   1,3,5(10)-OESTRATRIEN-3,17ALPHA-DIOL [J].
BUSETTA, B ;
BARRANS, Y ;
PRECIGOUX, G ;
HOSPITAL, M .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 1976, 32 (APR15) :1290-1292
[5]  
CHIEN YW, 1991, TARGETED DRUG DELIVE, P181
[6]   STRUCTURE OF CRYSTALLINE COMPLEX ESTRADIOL - UREA (1-1) [J].
DUAX, WL .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL CRYSTALLOGRAPHY AND CRYSTAL CHEMISTRY, 1972, B 28 (06) :1864-&
[7]  
ECKLE E, 1988, LIEBIGS ANN CHEM, P199
[8]   Statistical approach to optimization of drying conditions for a transdermal delivery system [J].
Lipp, R ;
Heimann, G .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1996, 22 (04) :343-348
[9]   An investigation into the melting behavior of binary mixes and solid dispersions of paracetamol and PEG 4000 [J].
Lloyd, GR ;
Craig, DQM ;
Smith, A .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (09) :991-996
[10]   Control of drug crystallization in transdermal matrix system [J].
Ma, XG ;
Taw, J ;
Chiang, CM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 142 (01) :115-119